Ángel Guerrero

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

Zuzana Kos, Elvire Roblin, Rim S. Kim et al. · npj Breast Cancer · 2020 · 206 citations · Full text

Medicine, Oncology, Pathology +16

Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy As First-Line Treatment for Advanced Breast Cancer: The Letrozole/Fulvestrant and Avastin (LEA) Study

Miguel Martín, Sibylle Loibl, Gϋnter von Minckwitz et al. · Journal of Clinical Oncology · 2015 · 133 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Predicting response and survival in chemotherapy-treated triple-negative breast cancer

Aleix Prat, Aňa Lluch, Joan Albanell et al. · British Journal of Cancer · 2014 · 113 citations · Full text

Medicine, Biostatistics, Oncology +16

Phase II trial with letrozole to maximum response as primary systemic therapy in postmenopausal patients with ER/PgR[+] operable breast cancer

Antonio Llombart‐Cussac, Ángel Guerrero, António Galán de Mera et al. · Clinical & Translational Oncology · 2012 · 71 citations

Medicine, Oncology, Pharmacology +13

Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapy-induced amenorrhea (CIA) who switched from tamoxifen to exemestane

Ángel Guerrero, J.G. Gavila, Elizabeth Folkerd et al. · Annals of Oncology · 2012 · 43 citations · Full text

Medicine, Gynecology, Oncology +12